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Introduction: Rivaroxaban does not require monitoring nor frequent dose adjustment. However, searching for
the optimal dose in the individual patient may be useful in some situations.
Aim: To determine which coagulation assay could be used to assess the impact of rivaroxaban on haemostasis
and provide guidelines for the interpretation of routine lab tests.
Materials: Rivaroxaban was spiked at concentrations ranging from 11 to 1090 ng/mL in plateletpoor plasma.
A large panel of coagulation assays was tested.
Results: A concentration dependent prolongation of aPTT, PT, dPT, PiCT was observed. PT and dPT were the
most sensitive chronometric assays but results varied depending on the reagent (Triniclot PT Excel
S>Recombiplastin 2 G>Neoplastin R>Neoplastin CI+>Triniclot PT Excel>Triniclot PT HTF>Innovin).
FXa chromogenic assays showed the highest sensitivity. In TGA, Cmax was the most sensitive parameter
with the tissue factor induced pathway. Rivaroxaban interferes on haemostasis diagnostic tests such the
measurement of clotting factors, ﬁbrinogen, antithrombin, proteins C and S, activated protein-C resistance
and Xa-based chomogenic assays.
Conclusions: PT may be used as screening test to assess the risk of bleedings. A more speciﬁc and sensitive
assay such as Biophen DiXaI using calibrators should be used to conﬁrm the concentration of rivaroxaban.
We also propose cut-off associated with a bleeding or thrombosis risk based on pharmacokinetic studies.
Standardization of the time between the last intake of rivaroxaban and the sampling is mandatory.© 2012 Elsevier Ltd. All rights reserved.Introduction
Rivaroxaban (Xarelto®) is a direct, antithrombin independent
and orally active FXa inhibitor that inhibits not only free FXa but
also the prothrombinase complex and clot bound FXa [1]. It is ap-
proved by the European Medicine Agency (EMA) [2] and the Food
and Drug Administration (FDA) [3] for the prevention of thrombo-
embolism in total hip replacement (THR) or total knee replacement
(TKR) and to prevent stroke in patients with non-valvular atrial ﬁ-
brillation (AF). The treatment of acute deep-vein thrombosis (DVT)
is an additional indication approved by the EMA [4]. It was also eval-
uated for secondary prevention after acute coronary syndrome [5]
and for thromboprophylaxis in acutely ill medical patients [6].
Rivaroxaban was found statistically superior to enoxaparin (versus
both European and North American regimen) in prevention of ve-
nous thromboembolism (VTE) and equivalent in term of bleedings32 81724299.
uxﬁls).
rights reserved.
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omb Res (2012), http://dx.din the orthopaedic indications [7]. In patients with non-valvular AF,
rivaroxaban was non-inferior to warfarin for the prevention of
stroke or systemic embolism and showed a similar rate of major
bleeding [8]. The net clinical beneﬁt of rivaroxaban, and other
NOACs, versus warfarin in patients with high risk of bleeding and
stroke, suggests a wider use of these compounds in the near future
[9].
The absolute bioavailability of rivaroxaban is high (80%– 100%).
In patients undergoing total hip replacement receiving Xarelto®
10 mg qd, median Cmax reaches 125 μg/mL (5th – 95th percentile:
91 – 196 μg/mL) andmedian Ctrough was 9 μg/mL (5th – 95th percen-
tile: 1 – 38 μg/mL) [10]. At the dose of 20 mg od in stroke prevention
in a simulated population of patients with non-valvular atrial ﬁbril-
lation, rivaroxaban has a Cmax of approximately 290 μg/L (5th –
95th percentile≈177 – 409 ng/mL) and a Ctrough of approximately
32 μg/L (5th – 95th percentile≈5 – 155 ng/mL) [11]. Similar drug
levels were found in patients receiving rivaroxaban 20 mg od for
the treatment of DVT [11].
Thanks to its predictable pharmacokinetic and pharmacodynamic
proﬁles, monitoring is generally not recommended [12]. However,ivaroxaban on coagulation assays: Laboratory recommendations for
oi.org/10.1016/j.thromres.2012.09.004
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od in several subgroups of patients [13]. Thus, in patients with severe
renal impairment (creatinine clearanceb30 mL/min) rivaroxaban
plasma levels may be signiﬁcantly increased that may lead to a mod-
erate increased bleeding risk [14]. The use of rivaroxaban is not
recommended in patients with creatinine clearanceb15 mL/min
and is to be used with “caution” in patients with creatinine clearance
between 15 to 29 mL/min. In addition, Xarelto® is a substrate of P-gp
transporter and is partially metabolized by CYP3A4 resulting in some
clinically relevant drug interactions [15]. Moreover, it should be used
with caution in cirrhotic patients with hepatic impairment (classi-
ﬁed as Child Pugh B) and is contraindicated in patients with hepatic
disease associated with a coagulopathy [16]. Therefore, biological
monitoring would be valuable in acute situations such as recurrent
thrombosis, bleedings, before urgent surgery, in case of bridging
and in case of at least two risk factors among the following: drug in-
teractions with caution, moderate renal impairment and moderate
hepatic impairment; Monitoring may also be useful in infants, preg-
nant women or in extreme body weights, although no relevant data
on drug levels associated with approximate therapeutic and harmful
ranges are currently available [17].
The primary aim of the present study is to assess which coagula-
tion assay(s) could be proposed to measure the pharmacodynamic
effects of rivaroxaban and to compare our results with those found
in the literature. Secondly, we also provide laboratory recommenda-
tions for the accurate determination of plasma drug concentration in
patients treated by rivaroxaban as well as a correct interpretation of
routine lab tests inﬂuenced by the presence of rivaroxaban.
Materials and methods
Rivaroxaban was spiked at increasing concentrations in pooled
citrated normal human platelet poor plasma (PPP) to measure Pro-
thrombin Time (PT), dilute PT (dPT), Prothrombinase-induced
Clotting Time (PiCT), Thrombin Generation Assay (TGA), Liquid
anti-Xa® (LAX) and Biophen Direct Factor-Xa Inhibitor® (DiXaI). Ac-
tivated Partial Thromboplastin Time (aPTT), activated clotting time
(ACT), Thrombin Time (TT), Ecarin Clotting Time (ECT) and Reptilase
Time (RT), Activated Protein C Resistance (APC-R), measurement of
clotting factors (XII; XI; IX; VIII; VII; V; X; II), Protein-C and free
Protein-S (immunological and clotting method) were also tested
and were described in supplementary material. The results pres-
ented for each clotting test represent the mean value and standard
deviation of the triplicate.
Testing solutions of rivaroxaban
Rivaroxaban was tested at 7 concentrations ranging from 11 to
1090 ng/mL (initial concentrations) in normal pooled plasma (NPP).
Rivaroxaban solutions were prepared as mentioned in the supple-
mentary material.
Whole blood and platelet-poor plasma
The protocol for whole blood and platelet-poor plasma is de-
scribed in the supplementary material.
Prothrombin time
Fifty μL of spiked NPP were incubated at 37 °C during 240 sec-
onds (sec) and mixed with 100 μL of calcium thromboplastin. The
different thromboplastin reagents used were Triniclot PT Excel® (Trin-
ity Biotech, Bray, Ireland), Triniclot PT Excel S® (Trinity Biotech),
Triniclot PT HTF® (Trinity Biotech), Neoplastin R® (Diagnostica
Stago, Asnieres, France), Neoplastin CI Plus® (Diagnostica Stago),Please cite this article as: Douxﬁls J, et al, Assessment of the impact of r
the monitoring of rivaroxaban and re..., Thromb Res (2012), http://dx.dInnovin® (Siemens Healthcare Diagnostics, Deerﬁeld, IL, USA) and
Recombiplastin® (Instrumentation Laboratory, Lexington, KY, USA).
Triniclot PT Excel®, Triniclot PT Excel S®, Neoplastin R®, Neo-
plastin CI Plus® are derived from rabbit brain. Recombiplastin® and
Innovin® are recombinant human thromboplastin. Triniclot PT
HTF® is derived from cultured human cells. Clotting time was mea-
sured on STA-R (Diagnostica Stago) for Neoplastin R®, Neoplastin CI
Plus®, Triniclot PT Excel®, Triniclot PT Excel S® and Triniclot PT
HTF®; on BCS (Siemens Healthcare Diagnostics) for Innovin® and
on ACL-TOP (Instrumentation laboratory) for Recombiplastin®.
Dilute prothrombin time (dPT)
Thromboplastin reagents were diluted with CaCl2 25 mM to ob-
tain an initial clotting time of approximately 30 sec. The dilutions
[one part of reagent/ x parts of CaCl2 solution] were: Innovin® dilut-
ed 1/100; Neoplastin CI Plus® diluted 1/128; NeoplastinR® diluted
1/256; Recombiplastin® diluted 1/64 and Triniclot PT Excel S® dilut-
ed 1/60.
One hundred and ﬁfty μL of spiked NPP were incubated during
120 sec at 37 °C. Thereafter, 150 μL of reagent was added, starting
the measurement on KC-10 (Amelung, Germany).
Thrombin generation assay (TGA)
The calibrated automated thrombin generation test (CAT) mea-
surement was performed as follows. Eighty μL of spiked-NPP, and
20 μL of PPP-Reagent High (20pM of Tissue Factor (TF) and 4 μM of
phospholipids (PL)), PPP-Reagent (5pM of TF and 4 μM of PL) or
PPP-Reagent LOW (1pM of TF and 4 μM of PL) were mixed in a
96-well microtiter plate (Thermo Immulon 2HB, Thermo Labsystems,
The Netherlands) and were incubated for 5 min at 37 °C. The plasma
clotting was then triggered by the addition of 20 μL of ﬂuorogenic
substrate (Z-Gly-Gly-Arg-AMC HCl)/calcium chloride buffered solu-
tion at 37 °C. A calibration curve was also performed using 70 μL of
NPP, 10 μL of PBS, 20 μL of Thrombin Calibrator and 20 μL of
substrate/calcium chloride-buffered solution at 37 °C. The substrate
hydrolysis was monitored on a microplate ﬂuorometer Fluoroskan As-
cent FL® (Thermo Labsystems, The Netherlands) with a 390/460 nm ﬁl-
ter set using the Thrombinoscope software (v 3.0, Thrombinoscope BV).
Chromogenic anti-Xa assays
STA® liquid anti-Xa (LAX) (diagnostica stago)
Thirty μL of spiked-NPP diluted 4-fold in Owren-Koller® were
mixed with 150 μL of chromogenic substrate (CBS 02.44 consisting
of MAPA-Gly-Arg-pNA .HCl) and incubated during 240 sec. Then,
150 μL of bovine FXa pre-warmed at 37 °C were added, starting the
measurement. Results are expressed in OD/min and measurements
were performed on STA-R.
Biophen direct Xa inhibitor® (DiXaI) (hyphen biomed)
Two hundred μL of spiked-NPP were diluted 50-fold in Tris-NaCl-
EDTA buffer at pH 7.85 with PEG6000 1% and sodium azide.
Seventy-ﬁve μL of human puriﬁed FXa were mixed with tested plas-
ma and incubated during 2 min at 37 °C. Seventy-ﬁve μL of, chro-
mogenic substrate (CS-11(65) consisting of -D-Arg-Gly-Arg-pNA,
2HCl) pre-warmed at 37 °C were added starting the measurement
on STA-R.
Statistical analysis
Sensitivity and reproducibility of the different assays were com-
pared using GraphPad Prism 5.01® for Windows®.
Sensitivity of a particular assay was deﬁned as the ﬁnal concentra-
tion in rivaroxaban needed to double (or halve)* the analyticalivaroxaban on coagulation assays: Laboratory recommendations for
oi.org/10.1016/j.thromres.2012.09.004
3J Douxﬁls et al. / Thrombosis Research xxx (2012) xxx–xxxparameter; (2xCT [CT=Clotting Time]; Cmax IC50* [The inhibitor con-
centration reducing the Cmax of 50%] and 2 x OD/min* [The concentra-
tion needed to halve the change in the optical density reported by
minute]).
Reproducibility expressed as CV (coefﬁcient variation=[(stan-
dard deviation/mean)*100]) of the triplicate for each concentration
and each test was determined. The minimum, mean and maximum
CV was determined for each test and compared between tests.
For PT, LAX and Biophen DiXaI, the intra- and inter-assays vari-
ability, expressed in mean CV, was also assessed by measuring 10 rep-
licates of 5 different concentrations (436; 218; 110; 22 and 0 ng/mL
in initial concentrations). The mean CV represented the sum of the
CV for the ﬁve concentrations divided by 5 (i.e. the number of concen-
trations). For the inter-assay variability, measures were performed
once a day during 10 days with the same lot of reagents.
The lower limit of quantitation was calculated as follow:
[(10*standard deviation of Y0)/ slope] where Y0 was the baseline
value of the linear regression. The upper limit of quantitation re-
ﬂects the concentration from which results were unreliable (con-
centration above 941 ng/mL in the initial sample were not tested).
For aPTT and PT, the dynamic range was calculated as the mean of
the individual lower and upper limit of quantitation of the different
reagents.
Results
Prothrombin time (PT)
Rivaroxaban showed a concentration-dependent prolongation of
PT (Fig. 1) depending on on the thromboplastin reagent used. The re-
lation was linear for each reagent. Two-fold CT was respectivelyFig. 1. Inﬂuence of rivaroxaban on PT. PT shows a concentration-dependent prolonga-
tion of clotting time. The sensitivity depends on the reagent. Triniclot PT Excel S® is the
most sensitive reagent while Innovin® seems to be the less affected thromboplastin.
The boxes in blue and red represent the therapeutic range in AF (rivaroxaban 20 mg
qd) at Ctrough and Cmax (median; 5th-95th percentile), respectively.
Please cite this article as: Douxﬁls J, et al, Assessment of the impact of r
the monitoring of rivaroxaban and re..., Thromb Res (2012), http://dx.d66 ng/mL for Triniclot PT Excel S®; 73 ng/mL for Recombiplastin®;
84 ng/mL for Neoplastin R®; 135 ng/mL for Neoplastin CI+®;
161 ng/mL for Triniclot PT Excel®; 180 ng/mL for Triniclot PT HTF®;
and 258 ng/mL for Innovin®. Results in terms of reproducibility are
summarized in Supplementary material: Table 2. The intra- and
inter-assay variability was respectively ranging from 2.2% and 1.9%
for Neoplastin R® to 7.7% and 8.4% for Triniclot PT HTF®.Diluted prothrombin time (dPT)
Dilute Prothrombin Time (dPT) showed a concentration-dependent
prolongation of clotting time also depending on the reagent (Fig. 2).
Two-fold CT was respectively 56 ng/mL for Recombiplastin® diluted
1/64; 99 ng/mL for Neoplastin CI+® diluted 1/128; 144 ng/mL for
Triniclot PT Excel S® and Neoplastin R® diluted 1/256, and 362 ng/mL
for Innovin® diluted 1/100. Results in terms of reproducibility were
summarized in Supplementary material: Table 2.Chromogenic anti-Xa assays
STA® liquid anti-Xa (LAX)
Liquid anti-Xa showed a concentration dependent decrease of
OD/min (Fig. 3). The relation was linear until 224 ng/mL but may be
correlated by an exponential model until 1090 ng/mL. Half OD/min
was 8 ng/mL and reproducibility (CV %) was 1.0%. The intra- and
inter-assay variability was respectively 1.3% and 1.9%.Biophen direct Xa inhibitor® (DiXaI)
Biophen DiXaI showed a concentration dependent decrease of
OD/min (Fig. 3). The relation was linear. Concentration of rivar-
oxaban required to halve the initial OD/min was 9 ng/mL and repro-
ducibility was 1.3%. The relation was linear until 545 ng/mL with a
decrease of sensitivity. The intra- and inter-assay variability was re-
spectively 3.4% and 3.9%.Thrombin generation assay (TGA)
The Peak and mVRI were the most sensitive CAT parameters with
a high sensitivity (Peak IC50 was 3 ng/mL with PPP-Reagent Low and
PPP-Reagent and was 14 ng/mL with PPP-Reagent High; mVRI IC50
was 1 ng/mL with PPP-Reagent Low and PPP-Reagent and 3 ng/mL
with PPP-Reagent High) and a low variability (CVb1.0%).Fig. 2. Inﬂuence of rivaroxaban on dPT: dPT shows a concentration-dependent prolon-
gation of clotting time. The sensitivity also depends on the reagent. Recombiplastin® is
the most sensitive reagent and Innovin® is less affected by rivaroxaban in comparison
with the other thromboplastin. The boxes in blue and red represent the therapeutic
range in AF (rivaroxaban 20 mg qd) at Ctrough and Cmax (median; 5th-95th percentile),
respectively.
ivaroxaban on coagulation assays: Laboratory recommendations for
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Fig. 3. Inﬂuence of rivaroxaban on Liquid anti-Xa (LAX) and Biophen DiXaI: LAX shows
a concentration-dependent decrease in OD/min. The relation is linear until 224 ng/mL.
LAX is the most sensitive assay with a concentration in rivaroxaban needed to halve
OD/min of 8 ng/mL. For Biophen DiXaI, the relation is linear until 545 ng/mL with a
concentration needed to halve OD/min of 9 ng/mL. For concentration higher than
545 ng/mL, the relation is no longer linear and a higher dilution (initially 50-fold) of
the sample is needed (data not shown). The boxes in blue and red represent the ther-
apeutic range in AF (rivaroxaban 20 mg qd) at Ctrough and Cmax (median; 5th-95th per-
centile), respectively.
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aPTT showed a concentration-dependent prolongation of clotting
time and also depended on the reagent (Supplementary material:
Fig. 1). Two-fold CT was respectively 208 ng/mL for CKPrest®;
234 ng/mL for Actin FS®; 258 ng/mL for Synthasil®; 375 ng/mL for
PTT-A® and 420 ng/mL for Cephascreen®. Results in terms of repro-
ducibility were summarized in Supplementary material: Table 2.
Prothrombinase-induced clotting time (PiCT)
PiCT showed a linear regressionwith 30 sec or 180 sec incubation
(Supplementarymaterial: Fig. 2). Two-fold CTwas 185 ng/mL for the
180 sec incubation methodology and for the 30 sec incubation
methodology 2xCT was different for fast half-life (2 ng/mL) and
short half-life (365 ng/mL). Reproducibility (mean CV %) was 0.4%
for PiCT 180 sec incubation and 5.6% for PiCT 30 sec incubation.
Activating clotting time (ACT)
ACT showed a concentration-dependent prolongation of clotting
time (Supplementary material: Fig. 3). Two-fold CT was 334 ng/mL
and reproducibility (mean CV %) was 17,0%.
Fibrinogen assay (clauss method); thrombin time (TT); reptilase time
(RT) and ecarin clotting time (ECT)
Rivaroxaban had no effect on the Clauss method ﬁbrinogen assay
(Supplementary material: Fig. 4) as well as on TT (Supplementary
material: Fig. 5), RT (Supplementary material: Fig. 6) and ECT (Sup-
plementary material: Fig. 7).
Discussion
Rivaroxaban (Xarelto®) is an orally, direct FXa inhibitor ap-
proved by the EMA [2] and FDA [3] in the prevention of DVT and pul-
monary embolism in TKR or THR and in stroke prevention in patients
with non-valvular atrial ﬁbrillation. Moreover, it has received the
market authorization in the treatment of acute DVT and prevention
of symptomatic VTE, in Europe only [2–4]. Thanks to its predictable
kinetics, therapeutic monitoring is generally not required. Neverthe-
less, this statement is debated [18,19]. As clearly highlighted by dif-
ferent authors, patients in clinical trials were carefully selectedPlease cite this article as: Douxﬁls J, et al, Assessment of the impact of r
the monitoring of rivaroxaban and re..., Thromb Res (2012), http://dx.dpatients, excluding those with assumed poor- compliance, renal in-
sufﬁciency and/or an increased bleeding risk. However, bleeding
and other side effects were still encountered at signiﬁcant percent-
ages [17].
Thus, the opportunity to further improve the efﬁcacy and safety of
new anticoagulants including rivaroxaban by searching for the opti-
mal dose in speciﬁc patients may require laboratory monitoring.
Moreover, such monitoring can be helpful in acute situations such
as recurrent thrombosis, bleedings, before urgent surgery, in case of
bridging, in infants, in pregnant women, in extreme body weight
and in case of at least two risk factors among the following: drug in-
teractions with caution, moderate renal impairment and moderate
hepatic impairment; Point measurement may also be useful in the
management of bleeding.
Aim of the study
Several studies have already been performed to suggest which
assay could be used to monitor patients on rivaroxaban but only
some of them compared the different reagents in terms of sensitivity,
reproducibility, linearity and/or speciﬁcity [20–22]. Nevertheless, in
clinical settings, practical approach is essential and no guidelines
have been provided to perform this measurement.
The primary objective of the present study is to specify which co-
agulation assays may be recommended to measure the effects of
rivaroxaban among a large range of tests and reagents (Table 1)
and to compare the results with those already published (Table 2).
The secondary objective is to propose recommendations about how
to perform this monitoring in clinical routine practise and how to in-
terpret the inﬂuence of rivaroxaban on routinely used laboratory
assays. We also propose cut-off associated with a bleeding or throm-
bosis risk based on pharmacokinetic studies but further investigation
in the ﬁeld and conﬁrmation are required.
Assessment of the pharmacodynamic effects of rivaroxaban: advantages
and drawbacks of different coagulation assays
Prothrombin time is usually used to assess vitamin K antagonist
therapy using the international normalized ratio (INR) and the inter-
national sensitivity index (ISI) speciﬁc to each reagent. Nevertheless,
INR using ISIVKA cannot be used for rivaroxaban. Authors have pro-
posed to use speciﬁc ISIrivaroxaban showing a reduction of the coefﬁ-
cient of variation between the slopes of the dilution curves and the
ratios of the thromboplastin reagents, but up to now this method re-
quired further investigations and standardization [23,24]. Thus, PT
showed a concentration dependent prolongation of clotting time with
a linear regression (Fig. 1). Two-fold CT depended on the clotting re-
agent used (2xCT was ranging from 66 ng/mL to 258 ng/mL in our
study). The most sensitive reagent in this study was Triniclot PT Excel
S®. Results obtained for PT reagents showed an important variability
between studies in terms of 2xCT. This may be explained by the fact
that, in the other studies, results in terms of sensitivity were not
expressed in ﬁnal concentration (in Table 2 our results are expressed
in initial concentration in order to allow direct comparison between
studies). By calculating sensitivity using the initial plasma drug concen-
tration instead of theﬁnal plasma drug concentration, resultswere con-
sistent with previous publications. A recent multicenter trial has
demonstrated that results expressed in rivaroxaban concentration
(ng/mL) did not show signiﬁcant difference (P>0.05) in the
interlaboratory variations of the PT measurement [25], suggesting
that the use of the widely available PT assay, in conjunction with
rivaroxaban calibrators, may be useful for the measurement of
peak plasma levels of rivaroxaban. Nevertheless, results were
obtained from spiked apheresis citrated-pooled plasma originating
from transfusion blood banks and further experiments in patient's
plasma should be investigated to know whether the interindividualivaroxaban on coagulation assays: Laboratory recommendations for
oi.org/10.1016/j.thromres.2012.09.004
Table 1
Summary of assays for the monitoring of rivaroxaban in plasma. (PT: Prothrombin Time; Biophen DiXaI: Biophen Direct Factor Xa Inhibitor; LAX: Liquid anti-Xa; dPT; dilute Pro-
thrombin Time; TGA: Thrombin Generation Assay; aPTT: activated Partial Thromboplastin Time; PiCT: Prothrombinase-induced Clotting Time; ACT: Activated Clotting Time; TT:
Thrombin Time; ECT: Ecarin Clotting Time).
Useful for
monitoring
Reliable but requires laboratory
experience
Not recommended
PT Biophen
DiXaI
LAX dPT TGA
(Peak IC 50)
aPTT PiCT ACT TT ECT
Sensitivity (ng/mL)† 66 to 258 9 8 56 to 362 3 to 14 208 to 420 185 334 Not Inﬂuenced Slightly Inﬂuenced
Dynamic range of quantitation (ng/mL) ‡ 80 – 1090 29 – 545 13 – 224 141 – 1090 N.D 164 – 1090 N.D N.D N.D N.D
Reproducibility (%) †† 0.5 to 1.3 1.3 0.9 1.1 to 1.9 1.0 0.9 to 4.4 0.4 to 5.6 17 N.D N.D
Dependence of reagent Yes No No Yes Yes Yes No Yes No No
Linearity of the response Yes Yes Yes Yes Yes No No No Not Inﬂuenced Yes
† Sensitivity expressed the concentration needed to double or halve the evaluated parameter (2 x clotting time (CT); ½ x OD/min; Peak IC50).
‡ The lower limit of quantitation was calculated as follow: [(10*standard deviation of Y0)/ slope]. The upper limit of quantitation reﬂects the concentration from which results
were unreliable (concentration above 1090 ng/mL in initial concentration were not tested).
†† Reproducibility was expressed as the coefﬁcient of variation [CV (standard deviation/mean*100)] of the triplicate for each concentration and each test.
5J Douxﬁls et al. / Thrombosis Research xxx (2012) xxx–xxxvariables of PT impact on the results. CoaguCheck XS, a PT test that
used a speciﬁc thromboplastin reagent that enables the measure-
ment on whole blood was also assessed in a previous study. It
showed a 2xCT of approximately 50 ng/mL as well as a low
inter-individual variation [22]. Thus, CoaguCheck XS may be one
good opportunity for monitoring but results have to be expressed
in ng/mL.
As suggested previously, dPT may increase the sensitivity by mim-
icking physiological conditions [22]. In this study, dPT was found
slightly more sensitive than PT only for Recombiplastin® (2xCT=
73 vs. 56 ng/mL) and Neoplastin CI+® (2xCT=135 vs. 99 ng/mL).
However, according to Samama et al., the relation for each dPT re-
agent was also linear (Fig. 2). Reproducibility was lower than PT
test probably due to the manual method (KC-10) used in our study.
Base on the same method (e.g. the addition of calcium chloride), an-
other proposal for assessing the anticoagulant activity of oral FXa in-
hibitors is to modify a PT assay by adding calcium chloride at a
different concentration (ﬁnal dilution: 1:2,25) and NaCl, as appropri-
ate, to the thromboplastin reagent to increase assay dynamic range
and improve sensitivity but this method has not yet been investigated
with rivaroxaban [26].
As presented in previous studies [20–22,27,28], aPTT showed a
concentration-dependent prolongation of clotting time (Supplemen-
tary material: Fig. 1). This relation is curvilinear suggesting that the
afﬁnity decreases for higher rivaroxaban concentrations. As for PT
and dPT, 2xCT depends on the reagent. These results clearly showed
that aPTT is less sensitive than PT or dPT as mentioned in earlier pub-
lications [22,29] but were not in agreement with results obtained by
Hillarp et al. [21] who demonstrated that aPTT was generally more
inﬂuenced by the presence of rivaroxaban than PT, especially with
Owrenmethod. Thus, one can conclude that PT is preferable to ensure
a quantitation of rivaroxaban due to its linearity in a broad range of
concentrations and its higher sensitivity.
At lower concentration of rivaroxaban (b200 ng/mL), there was a
shortening in clotting time using the two-step (180 sec incubation)
PiCT (Supplementary material: Fig. 2). This was in agreement with
previous study [22] and a reduction of incubation time (30 sec) was
voluntary performed to avoid this shortening. This may be explained
by an interaction between endogenous antithrombin (AT) and
rivaroxaban as this artefact was removed using AT-deﬁciency plasma
[22]. Nevertheless, results in terms of sensitivity were not consistent
with those previously published but the two graphics looked alike
(Supplementary material: Fig. 2) [22]. The explanation was that in
this study we used a two-phase association exponential relation ex-
pressing the 2xCT in low (b54 ng/mL) and high (>54 ng/mL) ﬁnal
concentration in rivaroxaban. In conclusion, due to its lack of lineari-
ty, this test is not useful to measure rivaroxaban.Please cite this article as: Douxﬁls J, et al, Assessment of the impact of r
the monitoring of rivaroxaban and re..., Thromb Res (2012), http://dx.dEcarin clotting time (ECT) was almost insensitive to rivaroxaban.
Ecarin converts prothrombin in meizothrombin [30], and rivar-
oxaban, by inhibiting FXa, acts only on the capacity of FXa to gener-
ate meizothrombin but not on the ecarin activity.
ACT, a bedside test currently used to monitor heparin therapy dur-
ing cardiac interventions, showed a linear prolongation of the clotting
time until 545 ng/mL (Supplementary material: Fig. 3). The sensitiv-
ity increases proportionally with the concentration of rivaroxaban.
However, 2xCT was 334 ng/mL that is less sensitive than PT, dPT or
aPTT (depending on the reagent). Moreover, its low reproducibility
(mean CV%=17.0%) is a limiting parameter already described in
other clinical applications [31,32]. Moreover, the sensitivity towards
FXa or thrombin inhibition depends on the composition of the re-
agent [31]. All of these limitations preclude the use of ACT to assess
rivaroxaban drug levels.
Thromboeslastography (TEG) was previously assessed [22].
Rivaroxaban induced a concentration dependent prolongation of
the TEG clotting parameters (R: the time of clot formation in min
and K: velocity of ﬁbrin formation in min) without any modiﬁcation
in the amplitude making this test promising to assess the impact of
rivaroxaban, but further studies are required [22].
In this study, two chromogenic anti-Xa assays were used and
compared with those already tested in the literature. Liquid
anti-Xa® (LAX) showed a very high sensitivity with a concentration
of rivaroxaban required to halve OD/min of 8 ng/mL (Fig. 3). This
chromogenic assay is also very reproducible with a mean CV of
1.0%. Its use in routine may be valuable to monitor patients on
rivaroxaban. The relation is described by a one-phase decay equa-
tion. However, the relation is linear for concentration in rivaroxaban
in the initial sample b224 ng/mL, suggesting that a more important
dilution for samples presenting an OD/min b0.25 units should be
performed (1/8 instead of 1/4). In addition, one should also keep in
mind that LAX may be inﬂuenced by the presence of heparin and
pentasaccharides (i.e. fondaparinux, idraparinux) and a more specif-
ic test is then required when clinicians will face in unconscious pa-
tients without information on the nature of the anticoagulant.
Biophen Direct Factor Xa Inhibitors® (DiXaI) showed, as LAX, a
high sensitivity (9 ng/mL). One of the strength of this chromogenic
assay is the use of Tris-EDTA-NaCl buffer making this test insensitive
to the presence of heparin or fondaparinux [33] and thus highly inter-
esting in case of switching therapy or with unconscious patients in
emergency for example. The relation was linear (Fig. 3). Thanks to
its speciﬁcity, its high sensitivity and the fact that it covers the thera-
peutic range, Biophen DiXaI seems to be the more accurate assay to
monitor patients on rivaroxaban. Nevertheless, speciﬁc calibration
for other direct FXa inhibitors marketed (or under development)
will be required to correctly assess the plasma drug level. Otherivaroxaban on coagulation assays: Laboratory recommendations for
oi.org/10.1016/j.thromres.2012.09.004
Table 2
Summary of assays performed in the different in-vitro studies: Results show the sensitivity as the expression of the concentration in rivaroxaban in the initial sample needed to
double (or halve) the evaluated coagulation parameter. (LT: Lag Time; TTP: Time to Peak; ETP: Endogenous Thrombin Potential; mVRI: mean Velocity Rate Index).⁎
Perzborn et
al. 2005
[29]
Gerotziafas et
al. 2007 [47]
Barret
et al.
2010
[20]
Hillarp et al. 2010
[21]
Samama et al. 2010
[33,48]
Asmis et al. 2011 [27] Detail of this study
TGA PPP-Reagent High NA NA NA NA NA NA LT: 73 ng/mL
TTP: 84 ng/mL
ETP: 767 ng/mL
Peak: 20 ng/mL
mVRI: 4 ng/mL
PPP-Reagent NA LT: 4 ng/ml
TTP : 4 ng/mL
ETP : 15 ng/mL
(Measure
performed on
PRP)
NA NA LT : 51 ng/mL
TTP : 45 ng/mL
ETP: 305 ng/mL
Peak: 21 ng/mL
mVRI: 9 ng/mL
NA LT: 80 ng/mL
TTP: 60 ng/mL
ETP: 141 ng/mL
Peak: 4 ng/mL
mVRI: 2 ng/mL
PPP-Reagent LOW LT: 93 ng/mL
TTP: 98 ng/mL
ETP: 98 ng/mL
Peak: 5 ng/mL
mVRI: 1 ng/mL
PT Neoplastin CI+® 229 ng/mL
Reagent is
not
speciﬁed
NA 546 ng/
mL
506 ng/mL 300 ng/mL NA 405 ng/mL
Neoplastin CI® 580 ng/
mL
NA 420 ng/mL NA NA
Innovin® 828 ng/
mL
591 ng/mL 700 ng/mL Results not expressed in
term of sensitivity
774 ng/mL
Recombiplastin® 642 ng/
mL
498 ng/mL 300 ng/mL 219 ng/mL
Thromborel S® NA 885 ng/mL 500 ng/mL NA NA
Technoplastin
HIS®
NA 557 ng/mL NA NA NA
SPA+® NA 1375 ng/mL NA NA NA
Nycotest PT® NA 1300 ng/mL NA NA NA
PT Owren® NA 891 ng/mL NA NA NA
Simple Simon PT® NA 871 ng/mL NA NA NA
Triniclot PT Excel® NA NA 450 ng/mL (type of
Triniclot is not
speciﬁed)
NA 483 ng/mL
Triniclot PT Excel
S®
NA NA NA 198 ng/mL
Triniclot PT HTF® NA NA NA 540 ng/mL
Neoplastin R® NA NA NA NA 252 ng/ml
aPTT Actin FSL® NA NA NA 435 ng/mL NA aPTT were performed to
show the inﬂuence of
the ingestion of
rivaroxaban on
coagulation test.
NA
PTT-A® 491 ng/mL 750 ng/mL 1125 ng/ml
aPTT SP IL® 530 ng/mL NA NA
Triniclot aPTT HS® 617 ng/mL NA NA
aPTT DG® 389 ng/mL NA NA
CKPrest® NA 550 ng/mL 624 ng/mL
PTT-LA® NA 650 ng/mL NA
Actin FS® NA 500 ng/mL 702 ng/mL
Synthasil® NA NA 774 ng/mL
Cephascreen® NA NA 1260 ng/mL
dPT Recombiplastin®
1/64
NA NA NA NA NA NA 168 ng/mL
Recombiplastin®1/
32
450 ng/mL NA
Neoplastin CI® 1/
32
250 ng/mL NA
Neoplastin CI+®
1/32
280 ng/mL NA
Innovin® 1/64 700 ng/mL NA
Thromborel S® 1/
64
200 ng/mL NA
Triniclot 1/
8 (reagent not
speciﬁed)
280 ng/mL NA
Neoplastin CI+®
1/128
NA 297 ng/mL
Triniclot PT Excel
S® 1/30
NA 432 ng/mL
Neoplastin R® 1/
256
NA 333 ng/mL
Innovin® 1/100 NA 1086 ng/mL
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Table 2 (continued)
Perzborn et
al. 2005
[29]
Gerotziafas et
al. 2007 [47]
Barret
et al.
2010
[20]
Hillarp et al. 2010
[21]
Samama et al. 2010
[33,48]
Asmis et al. 2011 [27] Detail of this study
PiCT® Incubation 30 sec NA NA NA NA 40 ng/mL Fast 2xCT: 6 ng/mL
Incubation 180 sec >1000 ng/mL 555 ng/mL
ACT NA NA NA NA NA NA 418 ng/mL
TT NA NA NA NA NA NA Not inﬂuenced
RT NA NA NA NA NA NA Not inﬂuenced
Liquid anti-Xa® NA NA NA NA NA NA 352 ng/mL
Biophen Direct Factor
Xa Inhibitor®
NA NA NA NA Sensitivity not
explored (graph
is not expressed
in ﬁnal
concentration)
NA 788 ng/mL
Dilute Russell's Viper
Venom Time
(dRVVT)
NA NA NA NA 80 ng/mL and
60 ng/mL for
dRVV Conﬁrm
NA NA
Rotachrom LMWH® NA NA 31 ng/mL NA Decrease in OD/
min
NA NA
Stachrom LMWH® NA NA NA NA Decrease in OD/
min
NA NA
Biophen Heparin 6® NA NA NA NA NA They just speciﬁed
that this test give
the same
[rivaroxaban] than
HPLC/MS-MS
NA
Fibrinogen (Clauss
method)
STA-Fibrinogen® NA NA NA NA Not inﬂuenced
FibriPrest® Almost
unaffected
NA
Fibrinogen C® NA
Dade Thrombin® NA
Multiﬁbren U® NA
Antithrombin Berichrom ATIII® NA NA NA Not inﬂuenced NA NA NA
Stachrom ATII® Not inﬂuenced Not Inﬂuenced
Coamatic LR® Inﬂuenced Inﬂuenced
APC Resistance assay Coatest APC Resis-
tance V®
NA NA NA Inﬂuenced NA NA Inﬂuenced
Pefakit APC resis-
tance Factor V
Leiden®
Not inﬂuenced
HepTest (30 sec incubation) NA NA NA NA 50 ng/mL NA NA
Thromboelastography NA NcA NA NA Modiﬁcation of
clotting
parameters (R
and K)
NA NA
⁎ Results in term of sensitivity are expressed in ﬁnal concentration to allow between test comparisons.
7J Douxﬁls et al. / Thrombosis Research xxx (2012) xxx–xxxchromogenic assays have already been performed also showing good
sensitivity but the requirement of calibrator sets is mandatory as
mentioned in a previous study [34]. In conclusion, anti-Xa chromo-
genic assays are preferable to PT assays to perform monitoring of
rivaroxaban due to the higher sensitivity, the ﬂexibility, the lower
intra- and inter-assay variability, the similar inter-laboratory preci-
sion [20,35] and, for Biophen DiXaI, its speciﬁcity against other
antithrombin-dependent inhibitors [33]. Nevertheless, anti-Xa chro-
mogenic assays are not widely available and their use could be difﬁ-
cult in emergency situations.
The TGA gives more information than traditional coagulation as-
says (chronometric or chromogenic) [36]. Rivaroxaban, by its mode
of action, acts on the ampliﬁcation phase of the coagulation process
as showed by its TGA proﬁle (Fig. 4). Between study's results showedPlease cite this article as: Douxﬁls J, et al, Assessment of the impact of r
the monitoring of rivaroxaban and re..., Thromb Res (2012), http://dx.dthe same tendency: Peak and mVRI are the most inﬂuenced parame-
ters. Indeed, in our study, TGA shows a Peak IC50 of 3 ng/mL with
PPP-Reagent and a 2 x Lag Time (LT) of 55 ng/mL. PPP-Reagent
Low is too sensitive. Thus, we recommend using PPP-Reagent or
PPP-Reagent High to assess rivaroxaban plasma samples with the
CAT analyser. These results show that TGA might be an accurate
assay to assess rivaroxaban but in clinical practise, the turnaround
time, the interindividual variability and the lack of standardisation
will be limitations [37].
Interference of rivaroxaban on haemostasis diagnostic tests
In the case of the exploration of a haemorrhagic event, speciﬁc
tests such as reptilase time (RT), ﬁbrinogen (Clauss and PT-derivedivaroxaban on coagulation assays: Laboratory recommendations for
oi.org/10.1016/j.thromres.2012.09.004
8 J Douxﬁls et al. / Thrombosis Research xxx (2012) xxx–xxxmethod (dFib)), TT and clotting factor activity may be used. In case of
thrombophilia, an activated protein C (APC) resistance, AT, protein C,
protein S and clotting factor assays may be required and thus, it is of
particular importance for the clinician to have information about
how these tests may be inﬂuenced by rivaroxaban.
Further tests were performed to evaluate the inﬂuence of
rivaroxaban on the rate of ﬁbrinogen, using the Clauss method. InFig. 4. Inﬂuence of rivaroxaban on Calibrated Automated Thrombogram (CAT) using
different inductors. The most sensitive parameters are the mVRI and the Peak whatev-
er the reagent that is used. PPP-Reagent Low is too sensitive and for higher concentra-
tion in rivaroxaban, the curve may be confounded with background noise. Thus,
PPP-Reagent and PPP-Reagent High are more suitable to evaluate CAT parameters of
rivaroxaban.
Please cite this article as: Douxﬁls J, et al, Assessment of the impact of r
the monitoring of rivaroxaban and re..., Thromb Res (2012), http://dx.dour study, using STA-Fibrinogen® (Diagnostica Stago) rivaroxaban
almost did not affect the rate of ﬁbrinogen, except for higher concen-
tration (>545 ng/mL) where a decrease of approximately 10% in the
rate of ﬁbrinogen was noted as mentioned by a previous study [21].
The dFib assay is also widely used and Mani et al. stated that the ef-
fect of rivaroxaban on dFib varies signiﬁcantly depending on the PT
reagent used [38]. Logically, neither RT nor TT was inﬂuenced by
rivaroxaban. The inﬂuence on AT was evaluated in a previous study
[21] and showed that the choice of AT assay is of importance to cor-
rectly evaluate the rate of AT. Indeed, asmentioned by Khor et al. [39]
AT deﬁciency may be measured by either FXa-based assay or by
thrombin-based assay. Berichrom ATIII® and Stachrom ATIII®, two
thrombin-based AT assays were not inﬂuenced by the presence of
rivaroxaban in comparison with Coamatic LR® based on FXa (in-
crease of 0.09 IU/mL per 100 ng/mL rivaroxaban) investigated in a
previous study [21] and conﬁrmed by our personal unpublished data.
The APC resistance assay was also investigated and the inﬂuence
was also dependent of the type of assay. Coatest APC Resistance V®
and the HemosIL APC Resistance V®, two aPTT-based assay, are
inﬂuenced by rivaroxaban while Pefakit APC resistance Factor V
Leiden® is a speciﬁc test using Russell Viper Venom from Daboia
Russelli to activate prothrombinase complex showing no interfer-
ence with rivaroxaban [21]. In case of thrombophilia testing,
rivaroxaban also interfere with the one-stage and chromogenic fac-
tor VIII:C assays [40] but do not inﬂuence the Coamatic® Protein-C
assay. Themeasurement of free Protein-S using latex ligand immunoas-
say (Hemosil® Free Protein S) was not inﬂuenced by rivaroxaban (Sup-
plementary material: Table 3) in comparison with the chronometric
method (Staclot® Protein S) where an over-estimation of approxi-
mately 15% per 100 ng/mL of rivaroxaban was found (Supplemen-
tary material: Table 3). In addition, a study showed that the presence
of rivaroxaban in plasma samples at pharmacological concentrations
(±250 ng/mL) can change the results of lupus anticoagulant (LAC)
determinations as measured with the ofﬁcially recommended assays
for the detection of LAC: the aPTT and the dRVVT [41]. Therefore the
use of Taipan snake venom time and Ecarin clotting time are useful to
determine the presence of LAC in patients treated by rivaroxaban
[41]. In addition, clinically relevant concentrations of rivaroxaban,
interfere with PT- and aPTT- based assays for the measurement of
clotting factor activity in plasma [42]. These results are conﬁrmed
by our data (Supplementary material: Table 3) but in our study
there is a lower inﬂuence of the presence of rivaroxaban for the fac-
tors in the extrinsic pathway. This may be explained by the fact that
the reagent used in this study (Innovin®) is less sensitive to
rivaroxaban than Thomborel S® which was used in a previous
study [22,42]. Nevertheless, when higher dilution of the plasma sam-
ple is performed a normalisation of the factor activity may be ob-
served. Thus we recommend to perform a wash out period of at
least 24 hours (preferred 48 hours) before testing, to use the less
sensitive PT- and aPTT-reagents and to increase the sample dilution
for clotting factor assays.
Delay between the drug intake and the blood sampling
Another point to consider is the delay between the last drug in-
take and the time of blood collection since assays are inﬂuenced by
rivaroxaban plasma concentration that depends on the pharmacoki-
netic properties [38]. Indeed, Cmax is reached after 2 to 4 hours [11]
and it seems to be preferable to collect sample at Ctrough to avoid mis-
interpretation due to a prolonged or shortened delay in the absorp-
tion phase where the variability in concentration is higher.
Nevertheless, Ctrough is inappropriate to evaluate a lack of efﬁcacy
in case of recurrent thrombosis with PT reagents due to lower sensi-
tivity and thus, more sensitive assays like anti-FXa chromogenic as-
says should be used. However, in case of bleedings, Ctrough could be
assessed with PT reagents since drug levels are higher in thisivaroxaban on coagulation assays: Laboratory recommendations for
oi.org/10.1016/j.thromres.2012.09.004
Table 3
Baseline, mean or median Ctrough and Cmax, and cut-offs associated with a risk of bleeding or with sub-therapeutic level for PT (Recombiplastin®, Neoplastin CI+®, Neoplastin R®,
Innovin®, Triniclot PT HTF®, Triniclot PT Excel®, Triniclot PT Excel S®), Biophen Direct FactorXa Inhibitor (DiXaI) and Liquid Anti-Xa (LAX) in the orthopaedic indication (A) and in
AF (B). The results are expressed in seconds and/or ratio of the clotting time of a NPP spiked with rivaroxaban divided by the clotting time of NPP without spiking. (NPP: Normal
Pooled Plasma; AF: Atrial Fibrillation; N.D.: Not Determined).
A. In Major Orthopaedic Surgery: rivaroxaban 10 mg qd.
Reagent Baseline time Clotting time
corresponding to
a sub-therapeutic
level at Ctrough
(i.e 1 ng/mL) †
Clotting time
corresponding to
median Ctrough
(i.e 9 ng/mL)
Clotting time
corresponding to
a risk of bleedings
at Ctrough
(i.e 38 ng/mL) ‡
Clotting time
corresponding to
a sub-therapeutic
level at Cmax
(i.e 91 ng/mL) †
Clotting time
corresponding to
median Cmax
(i.e 125 ng/mL)
Clotting time
corresponding to
a risk of bleedings
at Cmax
(i.e 196 ng/mL) ‡
Sec±SD Sec Ratio Sec Ratio Sec Ratio Sec Ratio Sec Ratio Sec Ratio
Recombiplastin® 12.1±0.2 12.2 1.01 12.6 1.04 14.2 1.17 17.1 1.42 19.1 1.58 22.9 1.89
Neoplastin CI® 15.7±0.5 15.8 1.00 16.1 1.02 17.2 1.09 19.3 1.23 20.6 1.31 23.3 1.48
Neoplastin R® 15.1±0.4 15.1 1.00 15.4 1.02 16.5 1.10 18.6 1.24 19.9 1.32 22.7 1.50
Innovin® 12.1±0.1 10.4 1.00 10.5 1.01 10.9 1.05 10.7 1.12 12.1 1.16 13.1 1.25
Triniclot PT HTF® 14.3±0.2 14.3 1.00 14.5 1.02 15.2 1.07 16.7 1.17 17.5 1.23 19.4 1.36
Triniclot PT Excel® 12.5±0.2 12.5 1.00 12.7 1.02 13.5 1.08 14.9 1.19 15.7 1.26 17.5 1.40
Triniclot PT Excel S® 16.2±0.7 16.3 1.01 16.9 1.05 19.2 1.19 23.6 1.46 26.3 1.63 32.1 1.98
OD/min±SD OD/min Ratio OD/min Ratio OD/min Ratio OD/min Ratio OD/min Ratio OD/min Ratio
Biophen DiXaI® 2.543±0.009 2.539 1.00 2.514 0.99 2.423 0.95 2.252 0.89 2.147 0.84 1.922 0.76
LAX® 1.013±0.012 1.007 0.99 0.970 0.96 0.846 0.83 0.654 0.65 0.553 0.55 0.399 0.39
† Sub-therapeutic level in the orthopaedic indication is deﬁned as the lower 5th percentile at Ctrough and Cmax.
‡ Plasmatic rate in the orthopaedic indication associated with a risk of bleeding is deﬁned as the upper 95th percentile at Ctrough and Cmax.
B. In Atrial Fibrillation or acute deep vein thrombosis: rivaroxaban 20 mg qd.
Reagent Baseline time Clotting time
corresponding to
a sub-therapeutic
level at Ctrough
(i.e 5 ng/mL) †
Clotting time
corresponding to
mean Ctrough
(i.e 32 ng/mL)
Clotting time
corresponding to
a risk of bleedings
at Ctrough
(i.e 155 ng/mL) ‡
Clotting time
corresponding to
a sub-therapeutic
level at Cmax
(i.e 177 ng/mL) †
Clotting time
corresponding to
mean Cmax
(i.e 290 ng/mL)
Clotting time
corresponding to
a risk of bleedings
at Cmax
(i.e 409 ng/mL) ‡
Sec±SD Sec Ratio Sec Ratio Sec Ratio Sec Ratio Sec Ratio Sec Ratio
Recombiplastin® 12.1±0.2 12.4 1.02 13.9 1.15 20,7 1,71 21,9 1,81 28.1 2.32 34,7 2,87
Neoplastin CI+® 15.7±0.5 15.9 1.01 17.0 1.08 21,8 1,38 22,6 1,44 27 1.72 31,6 2,01
Neoplastin R® 15.1±0.4 15.4 1.02 17.0 1.13 24,3 1,61 25,6 1,70 32.4 2.15 39,5 2,62
Innovin® 12.1±0.1 10.5 1.01 10.9 1.04 12,5 1,20 12,8 1,23 14.3 1.38 15,9 1,53
Triniclot PT HTF® 14.3±0.2 14.4 1.01 15.1 1.06 18,3 1,29 18,9 1,33 21.9 1.54 25,0 1,76
Triniclot PT Excel® 12.5±0.2 12.6 1.01 13.3 1.07 16,5 1,32 17,1 1,37 20.0 1.60 23,1 1,84
Triniclot PT Excel S® 16.2±0.7 16.6 1.03 18.8 1.16 28,8 1,78 30,6 1,89 39.8 2.46 49,4 3,06
OD/min±SD OD/min Ratio OD/min Ratio OD/min Ratio OD/min Ratio OD/min Ratio OD/min Ratio
Biophen DiXaI® 2.543±0.009 2.527 0.99 2.441 0.96 2.050 0.81 1.980 0.78 1.621 0.64 1.243 0.49
LAX® 1.013±0.012 0.989 0.98 0.869 0.86 0.483 0.48 0,435 0.43 0.256 0.25 0.149 0.15
† Sub-therapeutic level is deﬁned as the lower 5th percentile at Ctrough and Cmax.
‡ Plasmatic rate associated with a risk of bleeding is deﬁned as the upper 95th percentile at Ctrough and Cmax.
9J Douxﬁls et al. / Thrombosis Research xxx (2012) xxx–xxxsituation. Thus, different sampling seems to bemandatory to have an
efﬁcient estimation of drug exposure. In addition, the marketing au-
thorization holder should publish all relevant data on drug levels (i.e.
pharmacokinetic curve based on the time of administration) so that
it becomes clear what the approximate therapeutic ranges of labora-
tory tests outcome are [17].
Recommendation for an accurate monitoring of patients on rivaroxaban
As speciﬁc cut-offs associated with a risk of bleeding are currently
not available, we have used plasmatic range (5th-95th percentile) of
the different pharmacokinetic studies as cut-offs. In a simulated AF
population, rivaroxaban given 20 mg qd gave a mean Cmax after 2 –
4 h of 290 ng/mL (5th – 95th percentile≈177 – 409 ng/mL) and a
mean Ctrough after 24 h of 32 ng/mL (5th – 95th percentile≈5 –
155 ng/mL) [11]. In patients undergoing total hip replacement
receiving Xarelto® 10 mg qd, median Cmax reaches 125 ng/mL (5th –
95th percentile: 91 – 196 ng/mL) and median Ctrough is 9 ng/mL (5th –
95th percentile 1 – 38 ng/mL) [10]. Expected results in time or in
OD/min were presented for PT with the different reagents, for LAX
and for Biophen DiXaI (Table 3). Sensitivity of PT is dependent on
the reagent; therefore the use of PT for the monitoring of rivar-
oxaban requires a calibration for each lot on each instrument and
in each laboratory to deﬁne local cut-off values. One limitation ofPlease cite this article as: Douxﬁls J, et al, Assessment of the impact of r
the monitoring of rivaroxaban and re..., Thromb Res (2012), http://dx.dPT is the weak sensitivity in comparison with chromogenic assays
and some pre-analytical variables such as inappropriate proportion
between blood and anticoagulant or storage that inﬂuence the re-
sults [43,44]. Nevertheless, the intra-assay variability wasb than
10% and the inter-assay variability wasb than 15% whatever the re-
agent used in this study. Chromogenic anti-Xa assays are preferable
because they are less sensitive than PT to sample collection condi-
tions and variations in the amount of intrinsic pathway clotting fac-
tors among patients [20]. In addition, a recent study showed that
anti-factor Xa chromogenic assay using rivaroxaban and controls, is
suitable for the measurement of a wide range of rivaroxaban plasma
concentration [35]. Moreover, Biophen DiXaI appears to be insensi-
tive to the presence of antithrombin-dependent factor Xa inhibitor
(i.e: fondaparinux and LMWH) [33]. Nevertheless, as PT is less ex-
pensive than chromogenic assays, we recommend performing cali-
brated PT as a screening test and if value exceeds speciﬁc cut-offs,
calibrated chromogenic anti-Xa assays should be performed.
Limitation of the study
One limitation of this study is the fact that we used spiked plasma
and that the study is mono-centric. These results should therefore be
validated in patients receiving Xarelto®. Moreover, it is currently
unknown how coagulation assays are predictive for the bleedingivaroxaban on coagulation assays: Laboratory recommendations for
oi.org/10.1016/j.thromres.2012.09.004
10 J Douxﬁls et al. / Thrombosis Research xxx (2012) xxx–xxxrisk [45]. However, it is not ethically acceptable to expose patients to
high-risk overdose of rivaroxaban to study the impact on coagulation
tests. Freyburger et al. performed such analysis in patients undergo-
ing THR or TKR and their results showed a correlation with those
obtained in vitro [46] and Mani et al. stated in their papers that
their ex vivo ﬁndings are in accordance with the in vitro data pub-
lished by Hillarp et al. reinforcing the positive correlation between
in vitro and ex vivo data. An inter-individual variability is also men-
tioned in these studies conﬁrming the hypothesis that monitoring
may be valuable to minimize the risk in high-risk population and to
potentially improve the efﬁcacy by searching for the optimal dose
in particular patients.
Conclusion
In this study we showed that chromogenic anti-Xa assays and, to
a lesser extent, PT are clearly the most appreciate assays to measure
pharmacodynamic effects of rivaroxaban on the coagulation in rou-
tine practice. We therefore recommend performing calibrated PT as
a screening test and if value exceeds speciﬁc cut-offs, calibrated
anti-factor Xa chromogenic assays should be done. Rivaroxaban
also inﬂuenced routine coagulation assays such as measurement of
clotting factor, proteins C and S, antithrombin, activated protein-C
resistance, as well as determination of lupus anticoagulant both
depending on the reagent and the method that is used. The time be-
tween the drug intake and the sampling is primary to interpret cor-
rectly the results. Relevant data on drug levels associated with
approximate therapeutic and harmful ranges have been proposed
in this study but require conﬁrmation from speciﬁc pharmacokinetic
data in patients with recurrent thrombosis or bleedings to minimize
the risk associated with rivaroxaban.
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